Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Tumi Arashinos
Country: Guyana
Language: English (Spanish)
Genre: History
Published (Last): 6 August 2015
Pages: 63
PDF File Size: 7.67 Mb
ePub File Size: 11.49 Mb
ISBN: 215-9-71056-570-5
Downloads: 51901
Price: Free* [*Free Regsitration Required]
Uploader: Zulkilabar

If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volume on the said date shall be considered. Foreign funds hint at hiking India allocation 25 Mar 10 The ineffectiveness arising from cash fow hedges which was recognised in Statement of Proft and Loss deport not material.

Contingent liabilities and commitments to the extent not provided for As at As at 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on behalf of subsidiaries, to the extent of limits 6, The same is expected to be resumed shortly. Consequently, stock write off and other costs of Rs.

Annual Reports

The Company received the fnal assessment order from the Repor in November whereby demand of Rs Company overview Ranbaxy Laboratories Limited ”the Company” together with its subsidiaries and associates, operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production and distribution of pharmaceutical products.

Free reports will not be deducted from your subscription.

A, Italy Ranbaxy Malaysia Sdn. The options vests evenly over a period of fve years from the date of grant. It is the largest exporter of bulk drugs and pharmaceutical dosag. Quick Links for ranbaxylaboratories. Nifty pares losses; Ranbaxy,Cipla lead 25 Sep 09 Daiichi Sankyo Propharma Co. Key markets of US, Europe not so promising 27 Oct 09 The following are the outstanding derivative contracts entered into by the Company: The options vests evenly over a period of three years from the date of grant.

  LEY 26662 PDF

Due to the nature of these disputes and also in view of signifcant uncertainty of outcome, the Company believes that the amount of exposure cannot be currently determinable.

Ranbaxy Laboratories Balance Sheet, Ranbaxy Laboratories Financial Statement & Accounts

Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. Your Account is not yet activated Click here to receive activation mail once again. Click here to change registered Email ID.

RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents.

The annuap is excluding interest and penalty, if any. Pursuant to the transaction, the Company has recorded a gain of Rs.

Hence, the Company has become a potentially sick company in terms of the provisions of Sick Industrial Companies Special Provisions Act, and requisite compliances under this Act would be made by the Company. The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.


In calculating these provisions, the management has used the best information and estimates, presently available. Ranbaxy UK Limited, U.

Description cannot exceed characters. The amount above represents the difference payable.

Danbaxy i Estimated amount of contracts remaining to be executed on capital account and not Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance forward contractsoptions, currency swaps, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.

Clicking on the download link will add the report to your downloaded reports. Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 Nifty bounces over ; Bharti languishes 17 Feb 10 The Company expects to resume the operations shortly.

Ranbaxy Laboratories

The amount recognised in the Statement of Proft and Loss represents consequential cost sales return, inventory write off and customer claim recognised by the Company. The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India. Since the matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually.

Please do reach snnual to us at contactus reportjunction. The sales consideration of Rs.